Genetic variants in lipid metabolism are independently associated with multiple features of the metabolic syndrome

Lipids in Health and Disease

Edith JM Feskens¹  Martijn ET Dollé²  Sandra Imholz²  Jolanda MA Boer³  Cécile M Povel¹ 

[1] Division of Human Nutrition, Wageningen University, Wageningen, the Netherlands;Laboratory for Health Protection Research (GBO), National Institute for Public Health and the Environment (RIVM), Bilthoven, the Netherlands;Centre for Nutrition and Health (CVG), National Institute for Public Health and the Environment (RIVM), Bilthoven, the Netherlands

关键词: APOE;    CETP;    metabolic syndrome;    abdominal obesity;    HDL-cholesterol;   

Others  :  1212587
DOI  :  10.1186/1476-511X-10-118

 received in 2011-06-02, accepted in 2011-07-18,  发布年份 2011

【 摘 要 】

Background

Our objective was to find single nucleotide polymorphisms (SNPs), within transcriptional pathways of glucose and lipid metabolism, which are related to multiple features of the metabolic syndrome (MetS).

Methods

373 SNPs were measured in 3575 subjects of the Doetinchem cohort. Prevalence of MetS features, i.e. hyperglycemia, abdominal obesity, decreased HDL-cholesterol levels and hypertension, were measured twice in 6 years. Associations between the SNPs and the individual MetS features were analyzed by log-linear models. For SNPs related to multiple MetS features (P < 0.01), we investigated whether these associations were independent of each other.

Results

Two SNPs, CETP Ile405Val and APOE Cys112Arg, were associated with both the prevalence of low HDL-cholesterol level (Ile405Val P = < .0001; Cys112Arg P = 0.001) and with the prevalence of abdominal obesity (Ile405Val P = 0.007; Cys112Arg P = 0.007). For both SNPs, the association with HDL-cholesterol was partly independent of the association with abdominal obesity and vice versa.

Conclusion

Two SNPs, mainly known for their role in lipid metabolism, were associated with two MetS features i.e., low HDL-cholesterol concentration, as well as, independent of this association, abdominal obesity. These SNPs may help to explain why low HDL-cholesterol levels and abdominal obesity frequently co-occur.

【 授权许可】

   
2011 Povel et al; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Teran-Garcia M, Bouchard C: Genetics of the metabolic syndrome. Appl Physiol Nutr Metab 2007, 32:89-114.
• [2]Hong Y, Pedersen NL, Brismar K, de Faire U: Genetic and environmental architecture of the features of the insulin-resistance syndrome. Am J Hum Genet 1997, 60:143-152.
• [3]Bellia A, Giardina E, Lauro D, Tesauro M, Di Fede G, Cusumano G, Federici M, Rini GB, Novelli G, Lauro R, Sbraccia P: "The Linosa Study": Epidemiological and heritability data of the metabolic syndrome in a Caucasian genetic isolate. Nutr Metab Cardiovasc Dis 2009.
• [4]Bosy-Westphal A, Onur S, Geisler C, Wolf A, Korth O, Pfeufferm M, Schrezenmeir J, Krawczak M, Muller MJ: Common familial influences on clustering of metabolic syndrome traits with central obesity and insulin resistance: the Kiel obesity prevention study. Int J Obes (Lond) 2007, 31:784-790.
• [5]Henneman P, Aulchenko YS, Frants RR, van Dijk KW, Oostra BA, van Duijn CM: Prevalence and heritability of the metabolic syndrome and its individual components in a Dutch isolate: the Erasmus Rucphen Family study. J Med Genet 2008, 45:572-577.
• [6]Carmelli D, Cardon LR, Fabsitz R: Clustering of hypertension, diabetes, and obesity in adult male twins: same genes or same environments? Am J Hum Genet 1994, 55:566-573.
• [7]Benyamin B, Sorensen TIA, Schousboe K, Fenger M, Visscher PM, Kyvik KO: Are there common genetic and environmental factors behind the endophenotypes associated with the metabolic syndrome? Diabetologia 2007, 50:1880-1888.
• [8]Lusis AJ, Alan DA, Reue K: Metabolic syndrome: from epidemiology to systems biology. Nat Rev Genet 2008, 9:819-830.
• [9]van Dam RM, Boer JM, Feskens EJ, Seidell JC: Parental history of diabetes modifies the association between abdominal adiposity and hyperglycemia. Diabetes Care 2001, 24:1454-1459.
• [10]van den Berg SW, Dolle ME, Imholz S, van der AD, van 't Slot R, Wijmenga C, Verschuren WM, Strien C, Siezen CL, Hoebee B, Feskens EJ, Boer JM: Genetic variations in regulatory pathways of fatty acid and glucose metabolism are associated with obesity phenotypes: a population-based cohort study. Int J Obes (Lond) 2009, 33:1143-1152.
• [11]Povel CM, Feskens EJ, Imholz S, Blaak EE, Boer JM, Dolle ME: Glucose levels and genetic variants across transcriptional pathways: interaction effects with BMI. Int J Obes 2010, 34:840-5.
• [12]Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, Gordon DJ, Krauss RM, Savage PJ, Smith SC Jr, Spertus JA, Costa F: Diagnosis and management of the metabolic syndrome. An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Executive summary. Cardiol Rev 2005, 13:322-327.
• [13]Pendse AA, Arbones-Mainar JM, Johnson LA, Altenburg MK, Maeda N: Apolipoprotein E knock-out and knock-in mice: atherosclerosis, metabolic syndrome, and beyond. J Lipid Res 2009, 50:S178-182.
• [14]Zhou H, Li Z, Hojjati MR, Jang D, Beyer TP, Cao G, Tall AR, Jiang XC: Adipose tissue-specific CETP expression in mice: impact on plasma lipoprotein metabolism. J Lipid Res 2006, 47:2011-2019.
• [15]Barzilai N, Atzmon G, Schechter C, Schaefer EJ, Cupples AL, Lipton R, Cheng S, Shuldiner AR: Unique lipoprotein phenotype and genotype associated with exceptional longevity. JAMA 2003, 290:2030-2040.
• [16]Greenow K, Pearce NJ, Ramji DP: The key role of apolipoprotein E in atherosclerosis. J Mol Med 2005, 83:329-342.
• [17]Karagiannides I, Abdou R, Tzortzopoulou A, Voshol PJ, Kypreos KE: Apolipoprotein E predisposes to obesity and related metabolic dysfunctions in mice. Febs J 2008, 275:4796-4809. Epub 2008 Aug 4727
• [18]Ka G, Going SB, Fernandez ML, Milliken LA, Lohman TG, Bassford T, McNamara DJ: Cholesteryl ester transfer protein and lecithin:cholesterol acyltransferase activities in hispanic and anglo postmenopausal women: associations with total and regional body fat. Metabolism 2003, 52:282-289.
• [19]Thompson A, Di Angelantonio E, Sarwar N, Erqou S, Saleheen D, Dullaart RP, Keavney B, Ye Z, Danesh J: Association of cholesteryl ester transfer protein genotypes with CETP mass and activity, lipid levels, and coronary risk. JAMA 2008, 299:2777-2788.
• [20]Ruan X, Ma L, Wang S, Lindpaintner K, Liu X, Wang B, Peng Z, Ma X, Cheng M, Zhang J, Liu L, Wang X: TAQIB and I405V polymorphisms of CETP are moderately associated with obesity risk in the Chinese adult population. Acta Diabetol 2009, 47:217-24.
• [21]Arai T, Yamashita S, Hirano K, Sakai N, Kotani K, Fujioka S, Nozaki S, Keno Y, Yamane M, Shinohara E: Increased plasma cholesteryl ester transfer protein in obese subjects. A possible mechanism for the reduction of serum HDL cholesterol levels in obesity. Arterioscler Thromb 1994, 14:1129-1136.
• [22]Thompson JF, Durham LK, Lira ME, Shear C, Milos PM: CETP polymorphisms associated with HDL cholesterol may differ from those associated with cardiovascular disease. Atherosclerosis 2005, 181:45-53.
• [23]Dallongeville J, Lussier-Cacan S, Davignon J: Modulation of plasma triglyceride levels by apoE phenotype: a meta-analysis. J Lipid Res 1992, 33:447-454.
• [24]Oh JY, Barrett-Connor E: Apolipoprotein E polymorphism and lipid levels differ by gender and family history of diabetes: the Rancho Bernardo Study. Clin Genet 2001, 60:132-137.
• [25]Sima A, Iordan A, Stancu C: Apolipoprotein E polymorphism--a risk factor for metabolic syndrome. Clin Chem Lab Med 2007, 45:1149-1153.
• [26]Srinivasan SR, Ehnholm C, Wattigney WA, Bao W, Berenson GS: The relation of apolipoprotein E polymorphism to multiple cardiovascular risk in children: the Bogalusa Heart Study. Atherosclerosis 1996, 123:33-42.
• [27]Srivastava N, Achyut BR, Prakash J, Agarwal CG, Pant DC, Mittal B: Association of cholesteryl ester transfer protein (TaqIB) and apolipoprotein E (HhaI) gene variants with obesity. Mol Cell Biochem 2008, 314:171-177.
• [28]Arbones-Mainar JM, Johnson LA, Altenburg MK, Maeda N: Differential modulation of diet-induced obesity and adipocyte functionality by human apolipoprotein E3 and E4 in mice. Int J Obes (Lond) 2008, 32:1595-1605.
• [29]Olivieri O, Martinelli N, Bassi A, Trabetti E, Girelli D, Pizzolo F, Friso S, Pignatti PF, Corrocher R: ApoE epsilon2/epsilon3/epsilon4 polymorphism, ApoC-III/ApoE ratio and metabolic syndrome. Clin Exp Med 2007, 7:164-172.
• [30]Pardo Silva MC, Janssens AC, Hofman A, Witteman JC, van Duijn CM: Apolipoprotein E gene is related to mortality only in normal weight individuals: the Rotterdam Study. Eur J Epidemiol 2008, 23:135-142.
• [31]Volcik KA, Barkley RA, Hutchinson RG, Mosley TH, Heiss G, Sharrett AR, Ballantyne CM, Boerwinkle E: Apolipoprotein E polymorphisms predict low density lipoprotein cholesterol levels and carotid artery wall thickness but not incident coronary heart disease in 12,491 ARIC study participants. Am J Epidemiol 2006, 164:342-348.